XBIT xbiotech.com Final Profit

Corporate emblem and logo of xbiotech.com (XBIT)

The total financial result of XBiotech Inc. (XBIT) demonstrates profit dynamics, where the metric value stands at -0.05. XBiotech Inc. is accelerating antibody development through partnerships with scientific centers. Management is betting on development autonomy and patent protection. Despite the absence of mature products, a solid liquidity reserve and research potential ensure business resilience.

XBIT (XBiotech USA) Net Profit history from 07/04/2022 to 10/29/2026

Analytical breakdowns and data insights for company xbiotech.com (XBIT)

- stock value and consensus price forecast:
Market Price XBiotech|XBIT - Price Target Chart
- market capitalization data:
Market Value XBIT|XBIT - Real Price to Acquire Entire Company
- business book valuation details:
Accounting Value of a Share XBiotech|XBIT - Book Capitalization|Market Cap to Net Assets Ratio xbiotech.com|XBIT - Cumulative Company Assets
- debt and solvency information:
Total Debt to Capital XBiotech Inc.|XBIT - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital XBiotech|XBIT - Company Aggregate Debts|Debts to Book Value XBIT|XBIT - Company Long-Term Liabilities|Company Short-Term Indebtedness XBiotech|Quick Liquidity xbiotech.com
- net income and valuation multiples indicators:
XBIT - Net Profit
Fundamental valuation:XBIT XBiotech USA
Manufactured product of XBiotech Inc

The specific nature of XBiotech Inc. (XBIT), with its narrow focus on developing cancer antibodies, makes its financial stability dependent on clinical trial outcomes. By analyzing the company's aggregate net income, an investor evaluates the difference between all operating inflows and expenses, which allows for the rapid identification of discrepancies between the business's actual profitability and management's declarations, thereby protecting capital from the risks of an overheated asset.

Key competitors

Company Net Income BeiGene Oncology (ONC)|Company Net Income Halozyme Therapeutics|RVMD: Final Profit|Net Income AAPG (Ascentage Pharma)|CGON (CG Oncology Inc) - Final Profit|Net Profit URGN (UroGen)|BCAX - Net Income|PSNL: Net Income|ERAS - Net Profit|Delcath Systems (DCTH) - Company Net Income|Y-mAbs Therapeutics Inc - Final Profit|AURA (Aura Bio) - Net Profit|Company Net Income Candel CADL|Net Income ARAY (Accuray Incorporated)|sellaslifesciences.com - Company Profit|Net Profit ACTU (Actuate Therapeutics)|Citius Oncology Inc. - Company Net Income|TuHURA - Net Profit|Net Financial Result Protara Tx TARA|Fate Therapeutics, Inc. (FATE) - Company Net Income|Company Net Income Aadi Bioscience (WHWK)|Net Income TCRX|CSBR (Champions Oncology Corp) - Profit After Payment of Taxes|Net Profit CVM|OSTX - Company Net Income|Net Profit RADX (Radiopharm Theranostics Limited)|ARTV - Net Income|Adlai Nortye Limited - Net Profit|Final Profit VERU (Veru Inc)|TPST (Tempest Tx) - Net Income|Xilio Therapeutics - Final Profit|RENB (Renovaro Biosciences) - Net Profit|Mural Bio (MURA) - Net Financial Result|Company Net Income Kairos Pharma Ltd (KAPA)|onkuretherapeutics.com - Company Profit|Net Profit GDTC (CytoMed Therapeutics Limited)|CRIS - Net Income|APLM: Net Income|Net Financial Result tharimmune.com THAR|ADVB (advanbiomed.com) - Net Income|Company Profit GNPX|CLDI (Calidi Biotherapeutics Inc.) - Net Profit|Company Net Income SBFM|Net Profit XBIO|Net Financial Result salariuspharma.com|Purple Biotech Ltd. - Net Income|Profit After Payment of Taxes AONC (American Oncology Network Inc)|BeOne Medicines - Net Profit|Checkpoint Therapeutics Inc (CKPT) - Net Income|ELEV: Net Profit|iCAD (ICAD) - Net Profit|Company Net Income Ikena Oncology Inc.|Company Profit NTBL (Notable Labs Ltd)|Net Profit VIRX|Net Income MorphoSys Corporation MOR|Net Profit NAYA (NAYA Biosciences)|ascentage.com (AAPGV) - Company Net Income